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In modern medicine, the placebo response or placebo effect has often been regarded as a nuisance in basic
research and particularly in clinical research. The latest scientific evidence has demonstrated, however, that
the placebo effect and the nocebo effect, the negative effects of placebo, stem from highly active processes
in the brain that are mediated by psychological mechanisms such as expectation and conditioning. These
processes have been described in some detail for many diseases and treatments, and we now know that
they can represent both strength and vulnerability in the course of a disease as well as in the response to
a therapy. However, recent research and current knowledge raise several issues that we shall address in
this review. We will discuss current neurobiological models like expectation-induced activation of the brain
reward circuitry, Pavlovian conditioning, and anxiety mechanisms of the nocebo response. We will further
explore the nature of the placebo responses in clinical trials and address major questions for future research
such as the relationship between expectations and conditioning in placebo effects, the existence of a consis-
tent brain network for all placebo effects, the role of gender in placebo effects, and the impact of getting drug-
like effects without drugs.Introduction
Recent experimental work clearly demonstrates that a better un-
derstanding of the neurobiology and psychology of the placebo
and nocebo responses is of great importance, as it might have
profound implications for basic and clinical research and clinical
practice. In basic research, we can learn more about how psy-
chological processes affect CNS neurochemistry and how these
alterations subsequently shape peripheral physiology and end
organ functioning. The growing knowledge on the neurobiology
of the placebo/nocebo response will also affect the design of
clinical trials in which treatment is tested against a placebo. Fi-
nally, it might affect our health care system not only by initiating
a discussion on the ethical dimension of placebo treatment but
also by forcing us to reconsider the significance of the placebo
in clinical training and practice.
The dynamic progress in this field is not only reflected in the
constantly growing number of publications explicitly focusing
on the neurobiology and psychology of the placebo response,
but also in the structure and content of scientific meetings on
this topic. A 1999 symposium on the Mechanisms of Placebo
covered this research area with two presentations on ‘‘expecta-
tion/conditioning mechanisms’’ and ‘‘opioid mechanisms’’ (9th
World Congress on Pain, Vienna). In 2000, a NIH-sponsored
workshop assembled ten presenters (and more than 500 atten-
dants and discussants), mainly from the US, to cover the field
and to assess the state of the art (Guess et al., 2002). A more re-
cent symposium on the Mechanisms of Placebo/Nocebo Re-
sponse held in Tutzing, Germany, in 2007 and supported by
the Volkswagen Foundation, one of the major German research
funding agencies, brought together 45 speakers and experts
from eight countries with topics like ‘‘general concepts,’’ ‘‘learn-ing and memory,’’ ‘‘brain-immune interaction,’’ ‘‘Parkinson’s
disease and reward mechanisms,’’ ‘‘pain,’’ and ‘‘clinical-ethical
implications,’’ which reflect the steady growth of knowledge in
this research field.
This review summarizes (1) current neurobiological models of
the placebo response: expectations and reward, Pavlovian con-
ditioning, and anxiety mechanisms of the nocebo response; (2)
implications of insights into the placebo mechanisms for clinical
trials and testing; and (3) the main research questions currently
being discussed.
Comprehensive reviews focusing on the psychological (Price
et al., 2008; Klosterhalfen and Enck, 2006), neuropharmacolog-
ical/neuroanatomical (Colloca and Benedetti, 2005; Benedetti
et al., 1995; Pacheco-Lopez et al., 2006; Benedetti, 2008) and
methodological aspects of the placebo response (Colloca et al.,
2008; Klosterhalfen and Enck, 2008) have been recently pub-
lished elsewhere.
Current Models of the Placebo Response
A major insight from the recent publications on placebo is that
there seems not to be a single neurobiological or psychobiolog-
ical mechanism which is able to explain placebo and nocebo
phenomena in general. Instead, we have learned that different
mechanisms exist by which placebo or nocebo responses are
steered across diseases and experimental conditions.
Expectation and the Brain Reward Circuitry
It has been proposed that the placebo effect is mediated by the
brain reward circuitry (de la Fuente-Ferna´ndez et al., 2001; de la
Fuente-Ferna´ndez and Stoessl, 2002). Based on placebo stud-
ies with Parkinson’s patients (de la Fuente-Ferna´ndez et al.,
2004) and in experimental pain (Scott et al., 2007), it has beenNeuron 59, July 31, 2008 ª2008 Elsevier Inc. 195
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clinical improvement, are likely to play an important role in the
placebo effect. Thus, expectation may be closely tied to a tonic
activation of tegmental or prefrontal dopaminergic neurons,
which project to the dorsal and ventral striatum. In the expecta-
tion phase, prior to reward, there is uncertainty, and this is
reflected in sustained dopaminergic activation, which is maxi-
mized when the probability of reward is 0.5. It is known that
with a 0.5 probability of reward, 29% of dopaminergic cells are
tonically activated (Fiorillo et al., 2003). Conversely, both occur-
rence and nonoccurrence lead to virtually no tonic activation.
There is also phasic dopaminergic activation which takes place
after reward, and this is stronger when the reward has come
as a surprise. Therefore, uncertainty appears to heighten reward
mechanisms in this brain reward circuitry model.
Based on this information, the following neurobiological pla-
cebo mechanism has been proposed (de la Fuente-Ferna´ndez,
2004; de la Fuente-Ferna´ndez et al., 2004). When an interaction
(e.g., positive verbal suggestion) creates the possibility of a re-
ward, which in the case of placebo administration is represented
by the therapeutic benefit, certain cortical neurons become
active in relation to reward probability. These cells send direct
excitatory glutamatergic inputs to dopaminergic cell bodies
along with indirect inhibitory gamma amino butyric acid inputs
(de la Fuente-Ferna´ndez et al., 2002a; Fricchione and Stefano,
2005). The combination of these signals arriving at the dopami-
nergic neurons via direct and indirect pathways contributes to
the probability of tonic activation (de la Fuente-Ferna´ndez
et al., 2002b). Furthermore, it has been reported that neurons
in the prefrontal cortex, nucleus accumbens, and the caudate-
putamen display tonic activation during expectation of reward
(Schultz, 1998).
Compelling evidence of the involvement of reward mecha-
nisms in the placebo effect comes from recent brain imaging
studies on placebo analgesia. In fact, in a brain imaging study
in which both positron emission tomography and functional
magnetic resonance imaging were used, Scott et al. (2007)
tested the correlation between the responsiveness to placebo
and that to monetary reward. By using a model of experimental
pain in healthy subjects, they found that placebo responsiveness
was related to the activation of dopamine in the nucleus accum-
bens, as assessed by using in vivo receptor-binding positron
emission tomography with raclopride, a D2-D3 dopamine
receptor agonist. The very same subjects were then tested
with functional magnetic resonance imaging for activation in
the nucleus accumbens to monetary rewards. What these inves-
tigators found is a correlation between the placebo responses
and the monetary responses: the larger the nucleus accumbens
responses to monetary reward, the stronger the nucleus
accumbens responses to placebos.
This study strongly suggests that placebo responsiveness de-
pends on the functioning and efficiency of the reward system,
and this would explain, at least in part, why some individuals
respond to placebos whereas some others do not. Those who
have a more efficient dopaminergic reward system would also
be good placebo responders. Interestingly, Scott et al. (2007)
used an experimental approach that is typical of clinical trials,
whereby the subjects know they have a 50% chance to receive196 Neuron 59, July 31, 2008 ª2008 Elsevier Inc.either placebo or active treatment, and whereby no prior condi-
tioning was performed.
In a different study by the same group, Scott et al. (2008) stud-
ied the endogenous opioid and the dopaminergic systems in
different brain regions, including those involved in reward and
motivational behavior. Subjects underwent a pain challenge, in
the absence and presence of a placebo with expected analgesic
properties. By using positron emission tomography with 11C-
labeled raclopride for the analysis of dopamine and 11C-carfen-
tanil for the study of opioids, it was found that placebo induced
activation of opioid neurotransmission in the anterior cingulate,
orbitofrontal and insular cortices, nucleus accumbens, amyg-
dala, and periaqueductal gray matter. Dopaminergic activation
was observed in the ventral basal ganglia, including the nucleus
accumbens. Both dopaminergic and opioid activity were associ-
ated with both anticipation and perceived effectiveness of the
placebo. Large placebo responses were associated with greater
dopamine and opioid activity in the nucleus accumbens. There-
fore, as shown in the schema of the reward circuitry in Figure 1,
both dopamine and endogenous opioids have been found to be
activated in the nucleus accumbens after placebo administra-
tion, which indicates that these two neurotransmitters play a
key role in the modulation of the placebo response.
Pavlovian Conditioning of Placebo Effects:
Neuroimmune Responses
The behavioral conditioning of immune responses is based on
the intense crosstalk between the CNS and the peripheral im-
mune system (Meisel et al., 2005; Sternberg, 2006; Tracey,
2007). Commonly, in these approaches, experimental animals
are presented with a novel taste (e.g., saccharin) as conditioned
stimulus (CS) in the drinking water, and subsequently injected
with an agent that produces changes in immune status
Figure 1. Simplified Scheme of the Reward System
Placebo administration has been found to activate both dopamine and endog-
enous opioid peptides in the nucleus accumbens, thus suggesting an involve-
ment of reward mechanisms in some types of placebo effects (de la Fuente
Ferna´ndez et al., 2001; Scott et al., 2008). Note: the main propose of this
sketch is to focus on neural substrates of the reward system in the context
of the placebo response which, in this case, takes precedence over anatom-
ical accuracy.
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is re-presented at a subsequent time point, the animals avoid
drinking the saccharin, which is termed ‘‘conditioned taste aver-
sion’’ (CTA) (Garcia et al., 1955). Concomitantly, the animals
demonstrate a modification of immune parameters that com-
monly mimics the actual UCS effect (Ader, 2003). Ader and
Cohen (1975) demonstrated conditioned suppression of anti-
body production for the first time. Experimental evidence over
the last 25 years has shown behaviorally conditioned effects in
rodents, both in humoral and cellular immunity, with behavioral
conditioning able to re-enlist changes in lymphocyte circulation
and proliferation, cytokine production, natural killer (NK) cell ac-
tivity, and endotoxin tolerance (reviewed in Exton et al., 2001;
Ader, 2003; Pacheco-Lopez et al., 2006; Riether et al., 2008).
Regarding the neurobiological mechanisms, it was demon-
strated by employing the immunosuppressant cyclophoshamide
as a UCS that the insular cortex and the amygdala are key struc-
tures in behaviorally conditioned suppression of antibody pro-
duction (Ramı´rez-Amaya et al., 1996, 1998). In parallel, when
the calcineurin inhibitor and immunosuppressive agent cyclo-
sporine A was employed as a UCS in a taste aversion paradigm,
the behaviorally conditioned suppressive effect on lymphocyte
activity in the spleen, as well as cytokine production (interleu-
kin-2, interferon-g), was affected by brain excitotoxic lesions.
This shows that the insular cortex is essential to acquiring and
evoking this conditioned response in cellular immune functions.
In contrast, the amygdala seems to mediate the input of visceral
information necessary at acquisition time, whereas the ventro-
medial hypothalamic nucleus appears to participate in the output
pathway to the immune system, which is needed to evoke the
behaviorally conditioned immune response (Pacheco-Lopez
et al., 2005). On the peripheral efferent arm, these conditioned
effects are mediated via the splenic nerve through noradrenaline
and adrenoceptor-dependent mechanisms (Exton et al., 2001,
2002). The neural circuitry is illustrated in Figure 2.
A number of studies have meanwhile demonstrated the clinical
relevance of conditioned changes in immune function. Specifi-
cally, the morbidity and mortality of animals with autoimmune
disease was abated via conditioning using cyclophosphamide
(Ader and Cohen, 1982) or with cyclosporine (Klosterhalfen and
Klosterhalfen, 1990) as the UCS and, in addition, behavioral
conditioning prolonged the survival of heterotopic heart allograft
and significantly inhibited the contact hypersensitivity reaction
(Exton et al., 1998, 1999, 2000).
Experimental evidence also suggests that behavioral condi-
tioning of immunopharmacological drug effects is possible in
humans. Conditioned cyclosphosphamide-induced leucopenia
has been reported (Giang et al., 1996), along with a conditioned
immune response to the cytokine interferon-g (Longo et al.,
1999), as well as conditioned suppression of the ex vivo produc-
tion and mRNA expression of interleukin-2 and interferon-g, and
of the proliferation of peripheral lymphocytes (Goebel et al.,
2002). Allergic reactions have been shown to be affected by be-
havioral conditioning and emotional status (Kemeny et al., 2007).
However, more recently, it was demonstrated that the antihista-
minergic properties of the H1-receptor antagonist desloratadine
can be behaviorally conditioned in patients suffering from aller-
gic house-dust-mite rhinitis, as analyzed by subjective symptomscore, skin prick test, and decreased basophile activation (Goe-
bel et al., 2008). Interestingly, subjective symptom score and
skin reactivity, but not basophile activation, was reduced in
patients who where conditioned but not re-exposed to the
novel-tasting drink served as a CS. By contrast, only conditioned
patients who were re-exposed to the CS also demonstrated sig-
nificant inhibition in cellular immune activation. These data sup-
port earlier observations indicating that conscious physiological
pain and motor mechanisms are mainly affected by patients’
conscious expectations, whereas unconscious physiological
processes, such as hormone release or immune functions,
appear to be mediated by behavioral conditioning (Benedetti
et al., 2003).
Similar conditioning mechanisms have been found in the en-
docrine system. In one study aimed at differentiating the effects
of conditioning and expectation, plasma levels of both growth
hormone and cortisol were measured in different conditions
(Benedetti et al., 2003). In the first experimental condition, verbal
suggestions of growth hormone increase and cortisol decrease
were delivered to healthy volunteers, so as to make them expect
hormonal changes. These verbal instructions did not have any
effect on both hormones, and in fact no plasma concentration
Figure 2. Neural Substrates Involved in Behaviorally Conditioned
Immunosuppression in Rats
Brain excitotoxic lesions show that the insular cortex is essential to acquiring
and evoking this conditioned immunosuppressive response. In contrast, the
amygdala seems to mediate the input of visceral information necessary at ac-
quisition time, whereas the ventromedial hypothalamic nucleus appears to
participate in the output pathway to the immune system needed to evoke
the behaviorally conditioned immune response (CS, conditioned stimulus,
saccharin taste; UCS, unconditioned stimulus; CsA, cyclosporine A; BBB,
blood-brain barrier; CVOs, circumventricular organs; VMH, ventromedial
hypothalamic nucleus) (Pacheco-Lopez et al., 2005).Neuron 59, July 31, 2008 ª2008 Elsevier Inc. 197
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sumatriptan, a serotonin 5-HT1B/1D receptor agonist that stimu-
lates growth hormone and inhibits cortisol secretion, was admin-
istered for 2 days in a row and then replaced with a placebo on
the third day. A significant increase of growth hormone and
decrease of cortisol plasma concentrations were found after
placebo administration. These conditioned effects occurred
regardless of the verbal suggestions the subjects received. In
other words, the placebo mimicked the sumatriptan-induced
growth hormone increase, even though the subjects expected
a growth hormone decrease. Likewise, the placebo mimicked
the sumatriptan-induced cortisol decrease, even though the
subjects expected a cortisol increase. It can be assumed that
in this case the conditioned stimulus was represented by the
act of injecting the pharmacological agent (i.e., the context
around the treatment).
This experimental evidence demonstrates the potential appli-
cability of such behavioral conditioning protocols in clinical prac-
tice. However, in future studies it will be necessary to analyze the
kinetics of the behaviorally conditioned immunopharmacological
and endocrine response and to elucidate whether and to what
extent these conditioned responses can be reconditioned on
multiple occasions. Only with this information and more detailed
knowledge of the mechanisms behind the CNS-immune system
and CNS-endocrine system interaction will it be possible to
design conditioning protocols which can be employed in clinical
situations to the patients’ advantage.
Mechanisms of the Nocebo Effect
Compared to the placebo effect, much less is known about the
nocebo effect, since the induction of a nocebo response repre-
sents a stressful and anxiogenic procedure, thus limiting its
ethical investigation. The term nocebo (‘‘I shall harm’’) was intro-
duced in contraposition to the term placebo (‘‘I shall please’’)
by a number authors in order to distinguish the pleasing from
the noxious effects of placebo (Kennedy, 1961; Kissel and Bar-
rucand, 1964; Hahn, 1985, 1997). If the positive psychosocial
context, which is typical of the placebo effect, is reversed, the
nocebo effect can be studied. Therefore, it is important to stress
that the study of the nocebo effect relates to the negative psy-
chosocial context surrounding the treatment, and its neurobio-
logical investigation is the analysis of the effects of this negative
context on the patient’s brain and body. As for the placebo
effect, the nocebo effect follows the administration of an inert
substance, along with the suggestion that the subject will get
worse. However, the term nocebo-related effect can also be
used whenever symptom worsening follows negative expecta-
tions without the administration of any inert substance (Benedetti
et al., 2007b; Benedetti, 2008).
Brain imaging techniques have been crucial to understanding
the neurobiology of negative expectations, and most of this
research has been performed in the field of pain. Overall, nega-
tive expectations may result in the amplification of pain (Koyama
et al., 1998; Price, 2000; Dannecker et al., 2003) and several
brain regions, like the anterior cingulate cortex (ACC), the pre-
frontal cortex (PFC), and the insula, have been found to be
activated during the anticipation of pain (Chua et al., 1999; Hsieh
et al., 1999; Ploghaus et al., 1999; Porro et al., 2002, 2003;
Koyama et al., 2005; Lorenz et al., 2005; Keltner et al., 2006).198 Neuron 59, July 31, 2008 ª2008 Elsevier Inc.For example, Sawamoto et al. (2000) found that expectation of
a painful stimulus amplified the perceived unpleasantness of in-
nocuous thermal stimulation, and that these subjective hyperal-
gesic reports were accompanied by increased brain activations
in the anterior cingulate cortex (ACC), the parietal operculum
(PO), and posterior insula (PI). In another study by Koyama
et al. (2005), as the magnitude of expected pain grew, activation
increased in the thalamus, insula, PFC, and ACC. By contrast,
expectations of decreased pain reduced activation of pain-re-
lated brain regions, like the primary somatosensory cortex, the
insular cortex, and ACC. Likewise, Keltner et al. (2006) found
that the level of expected pain intensity altered the perceived
intensity of pain along with the activation of different brain
regions, like the ipsilateral caudal ACC, the head of the
caudate, the cerebellum, and the contralateral nucleus cuneifor-
mis (nCF).
Besides neuroimaging, pharmacological studies give us in-
sights into the biochemistry of the nocebo effect and of negative
expectations. For example, the antagonist action of CCK on
endogenous opioids (Benedetti, 1997) is particularly interesting
in the light of the opposing effects of placebos and nocebos. A
model has recently been proposed whereby the opioidergic
and the CCK-ergic systems may be activated by opposite
expectations of either analgesia or hyperalgesia, respectively.
In other words, verbal suggestions of a positive outcome (pain
decrease) activate endogenous m-opioid neurotransmission,
while suggestions of a negative outcome (pain increase) activate
CCK-A and/or CCK-B receptors. This neurochemical view of the
placebo-nocebo phenomenon, in which two opposite systems
are activated by opposite expectations about pain, is in keeping
with the opposite action of opioids and CCK in other studies
(Benedetti et al., 2007a). Interestingly, the CCK-antagonist
proglumide has been found to potentiate placebo-induced
analgesia, an effect that is probably due to the blockade of the
anti-opioid action of CCK (Benedetti et al., 1995; Benedetti,
1996). Therefore, CCK appears to play a pivotal role in the psy-
chological modulation of pain, antagonizing placebo-induced
opioid release on the one hand and mediating nocebo-induced
facilitation of pain on the other hand.
The involvement of CCK in nocebo hyperalgesia is likely to be
mediated by anxiety, as benzodiazepines have been found to
block both nocebo-induced hyperalgesia and the typical
anxiety-induced hypothalamus-pituitary-adrenal hyperactivity.
Conversely, the CCK antagonist, proglumide, has been found
to prevent nocebo hyperalgesia but not the hypothalamus-
pituitary-adrenal hyperactivity, which suggests two independent
biochemical pathways activated by nocebo suggestions and
anxiety (Figure 3).
More recent studies have found that nocebo effects are also
associated to a decrease in dopamine and opioid activity in
the nucleus accumbens, thus underscoring the role of the reward
and motivational circuits in nocebo effects as well (Scott et al.,
2008). In other words, the activation/deactivation balance of
both dopamine and opioids in the nucleus accumbens would
account for the modulation of placebo and nocebo responses.
Therefore, a complex interaction among different neurotransmit-
ters, such as CCK, dopamine, and opioids, occurs when either
placebos or nocebos are administered.
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Ever since the dawn of the first randomized placebo-controlled
trials testing new drugs and treatments in the middle of the last
century, and even before (Hill, 1990), placebo responses in clin-
ical trials have given rise to discussion and concern regarding
their mechanisms and have usually been regarded as a nuisance
or a barrier to a rational approach in modern drug development.
High placebo responses have induced false expectations re-
garding drug efficacy and resulted in the refusal of drug approval
in some cases, e.g., neurokinins in the treatment of depression
(Kramer et al., 1998; Enserink, 1999).
Not only do placebo responses in clinical trials impose signif-
icant limits to the testing of new compounds, but they are also
linked to the drug adherence and compliance of patients in
such trials in a paradoxical way. Patients that adhered to medi-
cation instructions by more than 80% showed better survival in
a coronary disease study (Coronary Drug Project Research
Group, 1980), and poor drug adherence in a myocardial infarc-
tion survivor study was associated with a higher risk of mortality
(Beta-Blocker Heart Attack Trial, Horwitz et al., 1990), irrespec-
tive of whether the active compound or a placebo was taken,
and regardless of other potential risk factors. This has been
attributed to the greater expectancies or beliefs, both in drug
and placebo responders that the medication may be of help, al-
though other factors, such as health behaviors, cannot be ruled
Figure 3. Mechanisms of the Hyperalgesic Nocebo Effect
Nocebo suggestions induce anticipatory anxiety, which activates two inde-
pendent pathways, the hypothalamus-pituitary-adrenal (HPA) axis on the
one hand and a CCK-ergic pronociceptive system on the other hand. Benzo-
diazepines act on anxiety, thus blocking both the HPA hyperactivity and the
CCK pronociceptive system. In contrast, CCK antagonists act on the pronoci-
ceptive system only, thus preventing nocebo hyperalgesia but not HPA-hyper-
activity (Benedetti et al., 2006). Note: the main propose of this sketch is to
focus on neural substrates of the hyperalgesic nocebo effect which, in this
case, takes precedence over anatomical accuracy.out completely. These findings have certainly fostered the devel-
opment of further experimental approaches to the placebo
phenomenon.
Attempts to unravel the mechanisms of the placebo response
in clinical trials have used meta-analytic approaches of the
placebo arm of trials—with mixed results. The placebo effect in
randomized controlled trials has been reported to be around
40% in functional disorders (Enck and Klosterhalfen, 2005) but
lower in depression (29%), bipolar mania (31%) (Sysko and
Walsh, 2007), and migraine (21%) (Macedo et al., 2008). The rea-
sons for these variable placebo response rates are unknown but
may include the sample size (Enck and Klosterhalfen, 2005), the
year of study (Walsh et al., 2002), design characteristics (Macedo
et al., 2006), and recruitment pattern (Kobak et al., 2007). Meta-
analyses can come to opposite conclusions on the same data
set, e.g., with respect to the direction of the effects of the number
of study visits on the placebo effect size (e.g., Pitz et al., 2005;
Patel et al., 2005), but this may be due to data extraction errors
that lead to false findings and conclusions (Gøtzsche et al.,
2007). Hro´bjartsson and Gøtzsche (2001, 2004) came to con-
clude that the placebo response appears to be powerful only be-
cause of a lack of ‘‘no treatment’’ control groups in most studies.
However, their argument has been challenged by data indicating
that among the trials they included into their meta-analyses,
those with endpoints regulated directly by the autonomic
nervous system do report stronger response to placebo treat-
ment, while endocrine and other endpoints are less responsive
(Meissner et al., 2007).
Other contributing factors to the placebo response rate in clin-
ical trials were: the origin of patients—response rates in migraine
prophylaxis were higher in Europeans than in North Americans
(Macedo et al., 2008), personal expectations (Linde et al., 2007)
and the loss thereof, e.g., in Alzheimer’s disease (Benedetti
et al., 2006), the study center (Ondo, 2007), and patient recruit-
ment and physician training (Kobak et al., 2007). A genetic contri-
bution to placebo responsiveness has been proposed (Bendesky
and Sonabend, 2005; Raz, 2008) but empirical evidence is still
lacking.
Because of the difficulties to reliably identify placebo re-
sponders and predicting placebo response rates in clinical trials,
different methodological attempts have been made to the way
(novel) drugs are tested against placebo.
The most traditional way to attempt to control for placebo
response in clinical trials was the use of a crossover design, in
which an individual patient serves as her/his own control, reduc-
ing the between-subject variability and the number of patients
studied. This model was almost completely abolished due to
the fact that blinding may be rather difficult in such studies (Bou-
tron et al., 2006), unless one is able to implement ‘‘active place-
bos’’ that mimic the side-effects of a compound without inducing
its main effects (Edward et al., 2005). Another conventional
model to control for placebo effects is the use a placebo run-in
phase prior to drug and placebo dispensing to identify and
exclude placebo responders: placebo responders tend to exhibit
less severe symptoms during run-in (Evans et al., 2004) and to
respond faster to treatment with symptom improvement (Go-
meni and Merlo-Pich, 2007) than patients in the drug arm.
Drug-free run-in periods have also been used to identifyNeuron 59, July 31, 2008 ª2008 Elsevier Inc. 199
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However, these results are not generalizable across medical
conditions, (Talleyn et al., 2006) since most of the variables
that are regularly documented at study initiation are related to
symptoms and disease characteristics rather than to individual
personality traits or states (Hyland et al., 2007). An extension of
placebo run-in periods are studies with multiple drug/placebo
phases that alternate, with or without washout periods in be-
tween (Kleveland et al., 1985). These models were more recently
requested again by drug approval authorities to account for vari-
able symptom courses and the alternation of symptom-free with
relapse periods in many chronic diseases. It has, however, been
shown that the placebo response in a first medication period
does not reliably predict the response (to drug or placebo) in
a second phase (Tack et al., 2005). If being a placebo responder
is a characteristic of an individual patient, study designs should
take this into account by employing a design with multiple (>2)
crossovers between placebo and drug and to randomize and
individualize in a ‘‘single-subject trials’’ (SST) the timing for run-in
and run-out for each phase (Madsen and Bytzer, 2002). In theory,
this should allow us to reliably distinguish placebo responders
from nonresponders. However, multiple crossovers with ran-
domly assigned treatment periods, with a complete random
order or a random starting day generate specific methodological
problems and need new statistical models before being applica-
ble in clinical drug testing.
In experimental laboratory research, a number of experimental
designs have been employed that may help to identify predictors
of the placebo response in the future. The so-called ‘‘balanced
placebo design’’ (BPD) was traditionally used in the testing for
placebo effects of frequently consumed everyday drugs such
as caffeine, nicotine, and alcohol (e.g., Dagan and Doljansky,
2006; Kelemen and Kaighobadi, 2007; Cole-Harding and
Michels, 2007). While one-half of the study sample receives pla-
cebo and the other half the drug, half of each group is receiving
correct information while the other half is receiving false informa-
tion on the nature of their study condition (drug or placebo)
immediately prior to drug testing, thus allowing to differentiate
between the ‘‘true’’ drug effect (those receiving the drug but
are told they received placebo) and the true placebo effect (those
receiving placebo but are told they received the drug). As is
evident, the BPD implies ‘‘deception’’ of the subjects (Miller
et al., 2005), which limits its suitability and acceptance outside
the laboratory and in patients for ethical reasons (Ehni and
Wiesing, 2008).
Hidden treatment (HT) or covert treatment is another option
that may be specifically useful for the test of drug effects in acute
and highly symptomatic conditions such as with postoperative
pain (Levine et al., 1981), anxiety, and motor dysfunction in Par-
kinson’s disease (Benedetti et al., 2004b; Lanotte et al., 2005). It
resembles some of the features of the SSTs (Madsen and Bytzer,
2002). In case of HT, the patient may receive a drug unnoticed in
terms of timing and dosage, and the drug effect (or its missing
action) can be determined independent of the patient’s expecta-
tions. Benedetti and colleagues demonstrated that under these
circumstances drugs commonly believed to have analgesic
properties such as CCK-antagonists failed to show any antinoci-
ceptive effects (Colloca et al., 2004). Evidently, HT can only be200 Neuron 59, July 31, 2008 ª2008 Elsevier Inc.applied with the patient agreeing prior to the test that she/he
may or may not receive a drug at all, which may raise other eth-
ical concerns (Machado, 2005), especially with the test of novel
compounds of unknown properties.
Finally, a free-choice paradigm (FCP), which maybe regarded
as a modification of the adaptive response design (Rosenberger
and Lachin, 1993) or the early-escape design (Vray et al., 2004)
may offer an alternative approach to common drug test proce-
dures. FCP allows the patient to choose between two pills, of
which one is the drug and one the placebo, at medication-dis-
pensing time; it is, however, essential that the patient does not
take both pills at the same time (hence, a technical or administra-
tive modus has to be implemented to prevent this and to prevent
over-dosage etc.), and that he/she may switch to the other con-
dition at any time (hence, the pharmacodynamics of the com-
pound under investigation have to be appropriate, e.g., the
speed of action, the feasibility of on-demand medication, etc.).
It would, on the other hand, allow assessment of drug efficacy
via the choice behavior rather than with symptomatic endpoints.
The FCP has been used occasionally in optimizing dosage of
drugs (Perkins et al., 1997; Pinsger et al., 2006) in clinical trials.
It bypasses many of the ethical concerns against the use of
placebos (Ehni and Wiesing, 2008), but its methodology and
statistics in assessing drug superiority over placebo have not
been validated (Zhang and Rosenberger, 2006).
Research Questions for Future Research
The experimental work on the neurobiological and neuropsycho-
logical mechanisms of the placebo/nocebo response from the
last decade has impressively increased our knowledge of this
long-known phenomenon. It became clear that these ap-
proaches will not only help us to better understand human phys-
iology but might have many practical consequences such as on
the design of clinical studies, our health care systems, in partic-
ular the doctor-patient relationship as well as the education of
medical care professionals. However, there are still numerous
open questions which urgently need to be addressed in future
studies.
The Relationship between Suggested
and Conditioned Placebo Effects
It has been postulated that the placebo response is generated by
two distinct mechanisms across clinical conditions, one of which
concerns suggestion and expectation, and one learning via Pav-
lovian conditioning (Benedetti et al., 2003; Klosterhalfen and
Enck, 2006). The relationship between these two is still unclear,
but it has been the subject of experimental research in recent
years. Benedetti et al. (2003) were able to demonstrate in exper-
imental pain and in Parkinson’s disease that conditioning is
actually mediated by expectations and that expectations do not
affect conditioned responses. Similar explanations have been
put forward, for example, that expectancies acquired through
verbal instructions might also be seen as conditioning stimuli
that reactivate earlier stimulus association (Klinger et al., 2007).
In a set of experiments, it has recently been demonstrated that
prior experience is able to shape placebo analgesia (Colloca and
Benedetti, 2006). Subjects that were conditioned to experience
placebo analgesia in an acute paradigm showed reduced pain
experiences for up to seven days and exhibited no extinction
Neuron
Reviewof responses in the range of minutes. However, placebo analge-
sia was reduced by prior exposure to negative painful experi-
ence. These data emphasize that previous experience with the
treatment of pain, both successful and unsuccessful, will have
lasting effects on how the second and subsequent treatments
of the same conditions are perceived. The analogy to clinical
conditions is evident, but relative. While experimental pain is
phasic and acute, clinical pain is usually chronic, long-lasting.
Whether and to what degree previous pain treatment contributes
to the experience of placebo analgesia in a clinical trial—usually
15%–20% of the effect size achieved under experimental pain
conditions (Vase et al., 2002)—probably needs to be tested
with a different experimental or clinical design. When experimen-
tal placebo analgesia was directly compared to pain relief in pain
patients, the data suggested that mechanisms counteracting
the proanalgesic effects of placebo suggestions are involved
(Charron et al., 2006).
It is puzzling to realize that, beyond the laws of Pavlovian learn-
ing studied for almost a century now, there is basically no model
available that allows us to predict the maintenance of a strong
placebo response in a clinical trial that may last for a year or
longer (e.g., Chey et al., 2004). According to these laws (Zim-
mer-Hart and Rescorla, 1974), any conditioned response should
diminish over time if no further pairing of the UCS (e.g., an effec-
tive drug) and the CS (a pill or injection) occurs but the CS is
presented alone. In such trials, extinction does not seem to
occur at all. Hence, one may speculate that if conditioning (learn-
ing) is part of this placebo response, it cannot be of a Pavlovian
nature. Alternatively, in the case of newly developed compound,
previous experience with a drug, or a similar compound, that
might shape the response can have been gained only by
generalization.
The other issue that requires attention is the clinical applicabil-
ity of conditioned and suggested placebo responses in daily
medicine, as many of the studies have so far been conducted
in the laboratory and with healthy subjects. One example of
a successful transfer from bench to bedside, however, has
been documented by studies demonstrating behaviorally condi-
tioned effects in peripheral immune responses (see above).
Is There a Consistent Brain Network
for All Placebo Effects?
The number of brain imaging studies on the placebo response
has increased greatly over the past few years, in particular in
the area of pain and placebo analgesia (Petrovic et al., 2002; Wa-
ger et al., 2004; Bingel et al., 2006; Kong et al., 2006; Price et al.,
2006), but also to a lesser degree with regard to neurological and
psychiatric diseases, such as Parkinson’s disease, depression,
or irritable bowel disorder (reviewed, e.g., by Benedetti et al.,
1995; Colloca and Benedetti, 2005; Beauregard, 2007; Lidstone
and Stoessl, 2007, Enck and Klosterhalfen, 2005).
As to experimental pain, different cortical (prefrontal cortex,
anterior cingulate gyrus, insula, supplementary motor area),
and subcortical structures (amygdala, periacqueductal gray,
thalamus) have been found to be involved in the placebo
response, and they seem to differentiate between the sensory
and the emotional/affective components of pain signals. PET
receptor-binding studies have provided direct evidence that
the m-opioid system involving the brain stem and elaborated cor-tical networks mediates placebo analgesia (Zubieta et al., 2005;
Wager et al., 2007), thus confirming previous studies on the
blockade of placebo analgesia by the opioid antagonist nalox-
one (Levine et al., 1978; Amanzio and Benedetti, 1999). It should
be noted that other neurochemical systems have been found to
contribute to the placebo effect, e.g., the dopaminergic system
(Scott et al., 2007, 2008) and CCK (Benedetti et al., 1995; Bene-
detti, 1996). It remains unclear, however, whether each of these
systems contributes to all placebo responses or only to those
under specific clinical and experimental conditions. Placebo
responses in Parkinson’s disease and pain have been linked to
a subcortical dopaminergic ‘‘reward’’ in the ventral striatum (de
la Fuente-Ferna´ndez et al., 2001; Scott et al., 2007); however,
the involvement of dopamine was recently questioned with re-
gard to the placebo response in experimental pain (Martikainen
et al., 2005). Nevertheless, it is worth mentioning that a possible
downstream effect of dopamine activation after placebo admin-
istration was found in the subthalamic nucleus, in which single
neurons changed their firing pattern (Benedetti et al., 2004a).
It is one of the drawbacks of imaging studies that they rely on
a stable and dominant activation pattern across all subjects,
since group means are necessary for adequate data analysis.
Therefore, placebo nonresponders in small samples of subjects
are frequently excluded or used as a type of control (Petrovic
et al., 2002; Leuchter et al., 2002; Nemoto et al., 2007). Assess-
ment of individual responsiveness to placebo (Chung et al.,
2007) is, however, necessary to advance the field.
Other neurophysiological and psychobiological mechanisms
of placebo analgesia and placebo response are currently being
discussed. Placebo analgesia following heat pain application
may change spinal cord pain processing via descending path-
ways (Matre et al., 2006), and expectations have been found to
alter spinal reflexes and the descending noxious inhibitory con-
trol (Goffaux et al., 2007). This raises an important issue that
needs to be addressed in future research: While for expecta-
tion-induced placebo responses, higher centers of the CNS
are needed, Pavlovian conditioning may also occur within the
peripheral neural circuitry, e.g., within the enteric nervous sys-
tem (Drucker and Sclafani, 1997). Whether this also relates to
conditioned placebo responses warrants further research.
The Role of Gender in Placebo Effects
Gender effects of the placebo response have rarely been docu-
mented in clinical trials but have occasionally been noted in
experimental settings (Flaten et al., 2006). However, whether
and to what extent gender differences may account for some
of the variance in the placebo imaging studies is unknown so
far. Cortical processing, independent of the placebo response,
has shown significant gender variation both in volunteers and
in patients with somatic and visceral pain (Paulson et al., 1998;
Berman et al., 2000) and with nonpainful stimuli (Sabatinelli
et al., 2004; Gizewski et al., 2006). Unfortunately, most imaging
studies on the placebo response have ignored the potential
role of gender (Klosterhalfen and Enck, 2008).
Gender effects in the placebo response were reported in an
experimental setting with placebo analgesia during ischemic
pain, whereby males responded to the manipulation of expec-
tancies through pain information, while women did not (Flaten
et al., 2006). However, an experimenter effect could not beNeuron 59, July 31, 2008 ª2008 Elsevier Inc. 201
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could have induced a reporting bias (Kallai et al., 2004). Gender
effects were also noted in an acupuncture trial with male and
female acupuncturists, with females inducing greater trust than
male experimenters (White et al., 2003). Employing a motion-
sickness paradigm, conditioning was effective predominantly
in women, while in the suggestion experiment, men exhibited
a significantly greater reduction in rotation tolerance and
responded more strongly to rotation and to suggestions than
women (Klosterhalfen et al., 2007). However, other data from
this group pointed toward the role of biological factors (e.g.,
the menstrual cycle) on processing of visceral and vestibular
sensations (Klosterhalfen et al., 2008b) and on differential effects
of stress hormone release on nausea and motion sickness
(Rohleder et al., 2006). These observations clearly show the ne-
cessity to investigate gender effects in the placebo and nocebo
responses.
The Impact of Obtaining Drug-like
Effects without Drugs
One of the most practical implications of the recent neurobiolog-
ical advances in placebo research is the possibility to induce, at
least in some circumstances, drug-like effects without the
administration of drugs. Throughout this review we have seen
that placebos can induce the activation of endogenous opioids
and dopamine, that placebo-conditioned responses of several
immune mediators can be obtained through behavioral condi-
tioning, and that nocebos activate the endogenous CCK-ergic
systems. The obvious consequence of these findings is their ex-
ploitation both in the clinic and in other areas of society, although
important ethical constraints have so far limited the development
of therapeutic paradigms with placebos.
As far as the clinic is concerned, it would be conceivable today
to use a translational approach whereby many experimental
protocols, so far carried out in animals and healthy volunteers,
could be applied to real medical conditions. For example, there
is compelling evidence that pharmacological conditioning can
induce powerful placebo responses when the real drug is re-
placed with a placebo. This phenomenon is well documented
in humans, for example in pain (Amanzio and Benedetti, 1999),
the immune system (Goebel et al., 2002), and the endocrine
and motor systems (Benedetti et al., 2003), although unfortu-
nately no systematic investigation has been done in a real clinical
setting. There are, however, some indications that the applica-
tion of placebo-induced drug-like effects without drugs is possi-
ble in the clinic. For example, Benedetti et al. (2004a) conditioned
Parkinson’s patients with repeated administrations of the anti-
Parkinson’s drug apomorphin before the surgical implantation
of electrodes for deep brain stimulation. Then, the investigators
replaced apomorphin with a placebo in the operating room
and obtained a powerful placebo reduction of muscle rigidity
that mimicked the effects of apomorphin during the previous
days. Although the effect was short-lasting (no longer than 20–
30 min), it was useful from a clinical point of view because the
patient improved and felt better for a while, thus making some
surgical procedures easier and faster. These drug-mimicking
effects could be particularly useful whenever the drug has impor-
tant side effects. For example, in the study by Benedetti et al.
(2004a), the presurgical apomorphin resulted in both clinical202 Neuron 59, July 31, 2008 ª2008 Elsevier Inc.improvement and some side effects, like dyskinesia, whereas
the placebo in the operating room induced improvement but
not dyskinesia.
Besides the clinic, there are also some other areas of society in
which the drug-like effects of placebos may have a strong
impact. In a very recent study, Benedetti et al. (2007b) used pla-
cebos in an experimental simulation of a sporting event, whereby
a placebo was given on the competition day after precondition-
ing with a narcotic in the training phase. In fact, after repeated
administrations of morphine in the training phase, its replace-
ment with a placebo on the day of the competition induced an
opioid-mediated increase in pain endurance and physical perfor-
mance, even though no illegal drug was administered. This
shows that athletes can be preconditioned with narcotics and
then a placebo given just before the competition, thus avoiding
the administration of illegal drugs on the competition day. These
narcotic-like effects of placebos raise the important question of
whether opioid-mediated placebo responses are ethically ac-
ceptable in sport or whether they should rather be considered
as a doping procedure in all respects. In the light of the distinc-
tion between drugs that are prohibited during and/or out of com-
petition, the preconditioning procedure may be deemed ethical
and legal for drugs that are prohibited only during competition,
like narcotics (World Anti-Doping Agency 2007, www.wada.
ama.org). However, it may also be considered illegal because
morphine administration is aimed at conditioning the subjects
for subsequent replacement with a placebo, which is supposed
to show morphine-like effects during the competition. This issue
is not easy to be resolved and needs both an ethical and a legal
discussion. In fact, doping is a matter of great public concern
today, and we should be aware that if a procedure like the one
described by Benedetti et al. (2007b) is performed, illegal drugs
in sport would no longer be discoverable, nor would they violate
the current antidoping rules.
Where Does Placebo Research Go from Here?
Despite the recent explosion of neurobiological placebo re-
search using sophisticated tools, such as neuroimaging, in vivo
receptor binding, and single-neuron recording in awake sub-
jects, our knowledge of the mechanisms underlying the placebo
effect is still in its infancy, and several issues need to be ad-
dressed in future research. The major questions to be answered
are where, when, how, and why placebo effects occur. In fact, we
need to know where they work exactly, that is, in which medical
conditions. For example, are all diseases and symptoms subject
to placebo effects? We also need to know when they work, that
is, whether there are special circumstances that are particularly
amenable to placebo effects. How they work is also a major
question, as we need to understand the brain mechanisms at
both the macroscopic (brain regions and their interactions with
body functions) and microscopic (cellular and molecular) level.
Finally, determining why placebo effects exist at all represents
a major scientific challenge, and meeting that challenge will
give us insights into the possible evolution of endogenous
healthcare systems.
Besides the profound implications of placebo research for a
better understanding of human biology, some practical aspects
should not be forgotten. For example, placebo and nocebo
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of new treatments, as high placebo responses sometimes distort
the effects of a therapy. If we can identify in more detail the major
mechanisms involved in placebo responsiveness, we could also
develop strategies aimed at minimizing placebo effects, thereby
uncovering the real effect of a therapy. Likewise, nocebo effects
can be a serious drawback, as negative reactions to drugs are
sometimes due to psychological effects rather than to specific
negative effects of the drug itself. Therefore, research aimed at
investigating nocebo mechanisms would enable us to disentan-
gle the negative effects of the drug from those of the psycholog-
ical state of the patient. In addition, a better understanding of the
neurobiology of the placebo and nocebo responses will form the
basis for designing behavioral protocols that can be employed
as supportive therapy together with standard pharmacological
regimen, the aim being to maximize the therapeutic outcome
for the patient’s benefit.
We believe that the future years will be characterized by
a deeper understanding of both the placebo and nocebo phe-
nomena, which in turn will give us profound insights into many
aspects of human biology.
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